background
sever
patient
novel
coronaviru
pneumonia
progress
rapidli
acut
respiratori
failur
aim
evalu
definit
efficaci
safeti
corticosteroid
treatment
sever
pneumonia
method
fortysix
hospit
patient
sever
pneumonia
hospit
wuhan
union
hospit
januari
februari
retrospect
review
patient
divid
two
group
base
whether
receiv
corticosteroid
treatment
clinic
symptom
chest
comput
tomographi
ct
result
compar
total
patient
receiv
intraven
administr
methylprednisolon
dosag
day
remain
patient
signific
differ
age
sex
comorbid
clinic
laboratori
paramet
two
group
admiss
averag
number
day
bodi
temperatur
back
normal
rang
significantli
shorter
patient
administr
methylprednisolon
compar
without
administr
methylprednisolon
vs
patient
administr
methylprednisolon
faster
improv
patient
without
administr
methylprednisolon
significantli
longer
interv
use
supplement
oxygen
therapi
iqr
vs
iqr
p
term
chest
ct
absorpt
degre
focu
significantli
better
patient
administr
methylprednisolon
data
indic
patient
sever
pneumonia
earli
lowdos
shortterm
applic
corticosteroid
associ
faster
improv
clinic
symptom
absorpt
lung
focu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
corona
viru
diseas
covid
first
report
late
decemb
origin
wuhan
china
transmit
hubei
provinc
throughout
china
even
countri
ongo
outbreak
alreadi
declar
world
health
organ
public
health
emerg
intern
concern
pheic
februari
confirm
case
sever
case
confirm
death
across
china
betacoronaviru
present
viral
pneumonia
high
infecti
respiratori
droplet
direct
contact
appear
greater
infect
lowercas
fatal
rate
compar
sever
acut
respiratori
syndrom
sar
middl
eastern
respiratori
syndrom
mer
moreov
patholog
featur
pneumonia
greatli
resembl
seen
sar
mer
show
diffus
alveolar
damag
cellular
fibromyxoid
exud
desquam
pneumocyt
hyalin
membran
format
indic
acut
respiratori
distress
syndrom
ard
corticosteroid
wide
use
therapi
ard
use
treat
sar
proof
efficaci
could
significantli
decreas
mortal
sever
sar
patient
howev
evidencebas
medic
evid
confirm
definit
efficaci
safeti
corticosteroid
treatment
sever
pneumonia
address
issu
perform
retrospect
studi
clinic
radiograph
outcom
treatment
without
corticosteroid
cohort
patient
sever
pneumonia
studi
patient
sever
pneumonia
januari
februari
isol
ward
union
hospit
huazhong
univers
scienc
technolog
union
hospit
sentinel
gener
hospit
locat
endem
area
wuhan
hubei
provinc
design
govern
treatment
infect
studi
approv
research
ethic
committe
tongji
medic
colleg
huazhong
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
univers
scienc
technolog
wuhan
china
verbal
consent
obtain
patient
enrol
diagnosi
pneumonia
studi
diagnos
accord
interim
guidelin
throat
swab
sampl
patient
collect
confirm
realtim
rtpcr
assay
use
nucleic
acid
detect
kit
accord
manufactur
protocol
shanghai
biogerm
medic
technolog
co
ltd
clinic
classif
accord
coronaviru
pneumonia
diagnosi
treatment
plan
trial
version
develop
nation
health
committe
peopl
republ
china
meet
follow
diagnos
sever
case
respiratori
distress
respiratori
rate
per
rest
state
mean
oxygen
arteri
blood
oxygen
partial
pressureoxygen
condit
older
year
complic
hypertens
diabet
coronari
diseas
cancer
pulmonari
heart
diseas
structur
lung
diseas
immunosuppress
individu
demograph
characterist
comorbid
symptom
clinic
paramet
laboratori
index
chest
comput
tomograph
ct
scan
find
extract
electron
medic
record
vital
sign
patient
temperatur
heart
rate
blood
pressur
respiratori
frequenc
oxygen
satur
monitor
daili
blood
test
complet
blood
count
liver
renal
function
creactiv
protein
inflammatori
factor
lactat
dehydrogenas
examin
everi
day
chest
ct
scan
perform
everi
day
assess
criteria
studi
dynam
chang
index
mention
statist
packag
social
scienc
version
spss
use
data
analysi
p
criterion
signific
continu
variabl
report
mean
standard
deviat
median
interquartil
rang
iqr
valu
categor
variabl
report
count
percentag
continu
variabl
compar
use
student
ttest
mannwhitney
u
test
categor
variabl
compar
use
fisher
exact
test
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
tabl
among
death
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
happen
patient
methylprednisolon
administr
one
receiv
methylprednisolon
treatment
among
patient
patient
suffer
fever
admiss
patient
receiv
methylprednisolon
therapi
remain
patient
dynam
chang
bodi
temperatur
patient
shown
figur
number
percentag
patient
whose
bodi
temperatur
decreas
normal
rang
differ
day
treatment
begin
report
follow
methylprednisolon
therapi
vs
methylprednisolon
therapi
day
vs
figur
median
rest
similar
patient
without
methylprednisolon
therapi
admiss
due
low
patient
receiv
oxygen
therapi
daili
patient
shown
figur
averag
everi
day
compar
patient
without
methylprednisolon
therapi
shown
figur
methylprednisolon
therapi
group
faster
improv
tabl
howev
term
chest
ct
scan
day
found
absorpt
degre
focu
significantli
better
patient
methylprednisolon
figur
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
patholog
process
sever
pneumonia
inflamm
reaction
character
destruct
deep
airway
alveolar
current
consid
lung
injuri
associ
direct
virusinduc
injuri
also
invas
trigger
immun
respons
lead
activ
immun
cell
monocyt
macrophag
blymphocyt
releas
larg
number
proand
antiinflammatori
cytokin
includ
tnf
overwhelm
secret
cytokin
caus
sever
lung
damag
manifest
extens
damag
pulmonari
vascular
endotheli
alveolar
epitheli
cell
well
increas
pulmonari
vascular
permeabl
lead
pulmonari
edema
hyalin
membran
format
histolog
examin
shown
diffus
alveolar
damag
mucin
exud
similar
acut
respiratori
distress
syndrom
patient
sever
pneumonia
aggrav
symptom
alway
occur
day
onset
therefor
import
strengthen
treatment
suppress
proinflammatori
respons
control
cytokin
storm
stage
major
patient
surviv
recov
overcom
period
corticosteroid
classic
immunosuppress
drug
import
stop
delay
progress
pneumonia
prove
effect
treatment
ard
addit
immunosuppress
activ
corticosteroid
antiinflammatori
role
reduc
system
inflammatori
decreas
exud
fluid
lung
tissu
promot
absorpt
inflammasom
prevent
diffus
alveolar
damag
reliev
hypoxemia
effect
protect
lung
prevent
progress
respiratori
insuffici
meanwhil
corticosteroid
induc
decreas
bodi
temperatur
help
allevi
poison
symptom
caus
hyperthermia
present
studi
patient
sever
pneumonia
markedli
increas
inflammatori
marker
crp
fer
signifi
occurr
inflammatori
reaction
phase
meanwhil
patient
develop
fever
cough
dyspnea
markedli
declin
oxygen
satur
earli
clinic
manifest
ard
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
base
believ
indictor
corticosteroid
admiss
treat
patient
judg
result
earli
applic
lowdos
corticosteroid
could
improv
treatment
effect
present
improv
hypoxia
fever
symptom
shorten
diseas
cours
acceler
focu
absorpt
benefit
condit
monitor
refin
manag
seriou
complic
caus
corticosteroid
happen
patient
addit
time
treatment
also
import
master
treatment
durat
choos
appropri
corticosteroid
formul
dosag
basic
principl
corticosteroid
formul
select
lie
follow
two
aspect
short
halflif
strong
penetr
abil
corticosteroid
formul
use
cohort
methylprednisolon
median
effect
corticosteroid
halflif
prove
associ
better
intens
immunosuppress
experi
dosag
durat
rout
methylprednisolon
administr
day
via
intraven
inject
nevertheless
specif
dosag
durat
individu
patient
determin
clinic
manifest
leucocyt
lymphocyt
count
inflammatori
index
lesion
rang
corticosteroid
treatmentinduc
complic
main
concern
common
complic
caus
corticosteroid
secondari
infect
fungi
bacteria
experi
secondari
infect
occur
patient
sever
pneumonia
sensit
fulldos
antibacteri
drug
immedi
ad
major
patient
prone
secondari
bacteri
infect
due
exud
accumul
lung
push
prophylact
use
antibiot
moxifloxacin
levofloxacin
cephalosporin
secondli
use
immun
regul
human
immunoglobulin
enhanc
immun
function
patient
experi
human
immunoglobulin
usual
use
critic
patient
dosag
gd
day
puls
therapi
thirdli
thymosin
secret
thymic
epitheli
cell
promot
matur
tlymphocyt
regul
function
cellular
immun
suggest
use
thymosin
hospit
cours
treatment
determin
accord
result
lymphocyt
test
fourthli
ensur
adequ
calor
protein
vitamin
intak
maintain
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
electrolyt
acidbas
balanc
common
complic
hyperglycemia
therefor
continu
blood
glucos
monitor
recommend
antidiabet
agent
use
necessari
uncommon
complic
caus
corticosteroid
gastrointestin
bleed
hypertens
venou
thrombosi
hypokalemia
paid
attent
us
prudent
use
corticosteroid
prevent
measur
essenti
prevent
deterior
elder
patient
comorbid
studi
sever
limit
first
studi
retrospect
singl
center
observ
research
small
size
extern
valid
cohort
therefor
unmeasur
confound
may
influenc
accuraci
result
secondli
studi
includ
midand
longterm
outcom
cohort
discharg
continu
followup
observ
need
conclus
data
indic
patient
sever
pneumonia
earli
lowdos
shortterm
applic
corticosteroid
associ
faster
improv
clinic
symptom
absorpt
lung
focu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
imag
chest
ct
scan
day
hospit
sever
pneumonia
patient
without
methylprednisolon
treatment
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
